Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-DOTA-Anti-CD38 Daratumumab in Conditioning Regimen for Allogeneic HCT in High-Risk AML, ALL, and MDS
NCT06287944Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Jul 2025
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 225Ac-DOTA-daratumumab in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), sponsored by City of Hope. Primary endpoints: Incidence of adverse events (CTCAE) at 2 years, Incidence of adverse events (Bearman) at 2 years and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
225Ac-DOTA-daratumumab
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06287944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06287944.